Outlook Therapeutics (OTLK) faces a pivotal FDA decision for Lytenava on December 31st, following two prior rejections and a ...

Here are the top 5 articles detailing the advancements in hematologic oncology from 2025. BTK inhibitors have revolutionized treatment for hematologic malignancies, butacquired BTK mutations often ...

Discover how lightweight, stateless Thin Clients with read-only OS architectures support compliance, extend hardware lifespan ...

Several users of the Trust Wallet Chrome extension report having their cryptocurrency wallets drained after installing a ...

Several users of the Trust Wallet Chrome extension report having their cryptocurrency wallets drained after installing a ...

For patients with relapsed or refractory multiple myeloma, treatment with teclistamab plus daratumumab is associated with a significant PFS benefit.

In a quarterly report filed with the U.S. Securities and Exchange Commission on November 14, 2025 ( SEC filing ), TREMBLANT CAPITAL GROUP disclosed a new position in CyberArk Software Ltd.

Ceralasertib in combination with Imfinzi (durvalumab) did not meet the primary endpoint of overall survival (OS) in the phase ...

The Volt pulsed-field ablation (PFA) system (Abbott) has been approved by the US Food and Drug Administration for the treatment of patients with atrial fibrillation (AF), according to a Monday ...

Google has launched an interactive digital hub preserving Route 66 history using AI, showcasing 33 roadside attractions including Santa Monica's endpoint.

The KINECT-DCP trial evaluated the efficacy and safety of valbenazine in patients with dyskinesia due to cerebral palsy who experience choreiform movements.